Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
BMC Cancer
|
December 18, 2008
The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer
Achim Weber, Ilka Kristiansen, Manfred Johannsen, et al.
Oncogene
|
April 18, 2002
The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model
Michael Lein, Klaus Jung, Bernhard Ortel, et al.
Oncology Reports
|
August 4, 2005
Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma
Venugopal Bhuvarahamurthy, Joerg Schroeder, Glen Kristiansen, et al.
Aktuelle Urologie
|
September 27, 2022
[Retrospective practice-related care research study on therapy of mCPRC with radium-223 dichloride]
Charlotte Jores, Frank König, Eva Hellmis, et al.
BMC Cancer
|
August 12, 2009
Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer
Carsten Kempkensteffen, Florian Rudolf Fritzsche, Manfred Johannsen, et al.
Journal of Cellular and Molecular Medicine
|
February 21, 2009
MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy
Monika Jung, Hans-Joachim Mollenkopf, Christina Grimm, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 17, 2008
Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients
Paul Gutwein, Anja Schramme, Nina Sinke, et al.
Aktuelle Urologie
|
November 24, 2022
[Osteoprotection in patients with bone metastatic castration-resistant prostate cancer (mCRPC): real-world data from Germany, presented by d-uo]
Christian Doehn, Jörg Klier, Manfred Johannsen, et al.
Aktuelle Urologie
|
November 24, 2022
[Osteoprotection in patients with non-metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen-deprivation therapy (ADT): Real-world data from Germany, presented by d-uo]
Jörg Klier, Frank König, Robert Schönfelder, et al.
JAMA Oncology
|
December 12, 2024
Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer
Charlie A Hamm, Patrick Asbach, Anna Pöhlmann, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
BMC Cancer
|
December 18, 2008
The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer
Achim Weber, Ilka Kristiansen, Manfred Johannsen, et al.
Oncogene
|
April 18, 2002
The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model
Michael Lein, Klaus Jung, Bernhard Ortel, et al.
Oncology Reports
|
August 4, 2005
Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma
Venugopal Bhuvarahamurthy, Joerg Schroeder, Glen Kristiansen, et al.
Aktuelle Urologie
|
September 27, 2022
[Retrospective practice-related care research study on therapy of mCPRC with radium-223 dichloride]
Charlotte Jores, Frank König, Eva Hellmis, et al.
BMC Cancer
|
August 12, 2009
Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer
Carsten Kempkensteffen, Florian Rudolf Fritzsche, Manfred Johannsen, et al.
Journal of Cellular and Molecular Medicine
|
February 21, 2009
MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy
Monika Jung, Hans-Joachim Mollenkopf, Christina Grimm, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 17, 2008
Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients
Paul Gutwein, Anja Schramme, Nina Sinke, et al.
Aktuelle Urologie
|
November 24, 2022
[Osteoprotection in patients with bone metastatic castration-resistant prostate cancer (mCRPC): real-world data from Germany, presented by d-uo]
Christian Doehn, Jörg Klier, Manfred Johannsen, et al.
Aktuelle Urologie
|
November 24, 2022
[Osteoprotection in patients with non-metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen-deprivation therapy (ADT): Real-world data from Germany, presented by d-uo]
Jörg Klier, Frank König, Robert Schönfelder, et al.
JAMA Oncology
|
December 12, 2024
Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer
Charlie A Hamm, Patrick Asbach, Anna Pöhlmann, et al.
Page
of 6